Report cover image

Aurora Kinase Inhibitor - Pipeline Insight, 2024

Publisher DelveInsight
Published Apr 01, 2024
Length 60 Pages
SKU # DEL18679269

Description

Aurora Kinase Inhibitor - Pipeline Insight, 2024



DelveInsight’s, “Aurora Kinase Inhibitor - Pipeline Insight, 2024” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Aurora Kinase Inhibitor pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
  • Global coverage
Aurora Kinase Inhibitor Understanding

Aurora Kinase Inhibitor: Overview

Aurora kinases, a family of serine/threonine kinases, consisting of Aurora A (AURKA), Aurora B (AURKB) and Aurora C (AURKC), are essential kinases for cell division via regulating mitosis especially the process of chromosomal segregation.

Function – Aurora A kinase localizes mainly to the centrosomes and is important for centrosome maturation and separation, which in turn are essential for mitotic entry and bipolar spindle assembly. AuroraB is a component of chromosome passenger complex (CPC), composing of additional three activation regulators INCEP, survivin and borealin. It mediates chromosome condensation by phosphorylating histone H3 on Ser10 and variant centrosome protein A (CENP-A) on Ser7.

Aurora Kinase Inhibitors - All three members of the Aurora kinase family are overexpressed in multiple solid tumors, which is perhaps not surprising considering their functions in cell division. As more and more small-molecule Aurora kinase inhibitors are being developed, these inhibitors can be used not only for cell-biological studies on the functions of Aurora kinases, but also for developing new anti-cancer drugs. These inhibitors obstruct Aurora kinases, which in turn leads to aberrant mitosis. As a result, the p53-dependent checkpoint is activated and results in the induction of a G1-like cell-cycle arrest.

Aurora Kinase Inhibitor Emerging Drugs Chapters

This segment of the Aurora Kinase Inhibitor report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Aurora Kinase Inhibitor Emerging Drugs
  • Alisertib: Takeda Oncology
Alisertib (MLN8237) is an oral, selective, inhibitor of Aurora A kinase being investigated by Takeda for the treatment of small cell lung cancer. Aurora A kinase is required for cells to divide properly and has been shown to be over-expressed in a variety of cancers, and inhibition of Aurora A kinase represents a novel approach in cancer research. The drug is currently in phase 2 stage of development for the treatment of Acute myeloid leukaemia
  • Chiauranib: Chipscreen Biosciences
Chiauranib has a new chemical structure which is under global patent protection. The compound is independently designed and developed by Chipscreen Biosciences. It is a highly-selective Aurora B, CSF1R, VEGFR/PDGFR/c-Kit inhibitor, which exerts a comprehensive anti-tumor effect by simultaneously inhibiting tumor angiogenesis, inhibiting tumor cell mitosis and regulating tumor microenvironment. Chiauranib has shown pharmacological activity superior to that of other similar drugs in animal studies. In the meantime, it has an excellent safety profile despites being a multi-target kinase inhibitor. Chiauranib as a single agent therapy inhibits the overactive Aurora B pathway existed in and related to molecular mechanism of SCLC, which is an important feature of Chiauranib distinct to other antiangiogenic drugs. The drug is currently in phase 3 stage of development for the treatment of Small cell lung cancer.

Further product details are provided in the report……..

Aurora Kinase Inhibitor: Therapeutic Assessment

This segment of the report provides insights about the different Aurora Kinase Inhibitor drugs segregated based on following parameters that define the scope of the report, such as:
  • Major Players working on Aurora Kinase Inhibitor
There are approx. 10+ key companies which are developing the Aurora Kinase Inhibitor. The companies which have their Aurora Kinase Inhibitor drug candidates in the most advanced stage, i.e. phase III include, Chipscreen Biosciences.
  • Phases
DelveInsight’s report covers around 10+ products under different phases of clinical development like
  • Late-stage products (Phase III and
  • Mid-stage products (Phase II and
  • Early-stage products (Phase I/II and Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration
Aurora Kinase Inhibitor pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
  • Infusion
  • Intradermal
  • Intramuscular
  • Intranasal
  • Oral
  • Parenteral
  • Subcutaneous
  • Topical.
  • Molecule Type
Products have been categorized under various Molecule types such as
  • Vaccines
  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Aurora Kinase Inhibitor: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Aurora Kinase Inhibitor therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Aurora Kinase Inhibitor drugs.

Report Highlights
  • The companies and academics are working to assess challenges and seek opportunities that could influence Aurora Kinase Inhibitor R&D. The therapies under development are focused on novel approaches for Aurora Kinase Inhibitor.
Aurora Kinase Inhibitor Report Insights
  • Aurora Kinase Inhibitor Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs
Aurora Kinase Inhibitor Report Assessment
  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs
Key Questions

Current Scenario and Emerging Therapies:
  • How many companies are developing Aurora Kinase Inhibitor drugs?
  • How many Aurora Kinase Inhibitor drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for Aurora Kinase Inhibitor?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Aurora Kinase Inhibitor therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Aurora Kinase Inhibitor and their status?
  • What are the key designations that have been granted to the emerging drugs?
Key Players
  • Takeda Oncology
  • Chipscreen Biosciences
  • Aptose Biosciences
  • Eli Lilly and Company
  • AstraZeneca
  • Nerviano Medical Sciences
  • Advenchen Laboratories
  • TransThera Biosciences
  • Abbott Laboratories
  • Sumitomo Dainippon Pharma Oncology
  • GlaxoSmithKline
  • Sareum
Key Products
  • Alisertib
  • Chiauranib
  • Luxeptinib
  • AK 01
  • AZD 2811
  • Danusertib
  • AL 8326
  • TT 00420
  • Ilorasertib
  • Dubermatinib
  • GSK-1070916
  • Research programme: dual aurora/FLT kinase inhibitors

Table of Contents

60 Pages
Introduction
Executive Summary
Aurora Kinase Inhibitor: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Aurora Kinase Inhibitor – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Aurora Kinase Inhibitor companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Aurora Kinase Inhibitor Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Chiauranib : Chipscreen Biosciences
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Alisertib: Takeda Oncology
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
Comparative Analysis
AK 01: Eli Lilly and Company
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Aurora Kinase Inhibitor Key Companies
Aurora Kinase Inhibitor Key Products
Aurora Kinase Inhibitor- Unmet Needs
Aurora Kinase Inhibitor- Market Drivers and Barriers
Aurora Kinase Inhibitor- Future Perspectives and Conclusion
Aurora Kinase Inhibitor Analyst Views
Aurora Kinase Inhibitor Key Companies
Appendix

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us